Constraint on the solar Δm2\Delta m^2 using 4,000 days of short baseline reactor neutrino data

There is a well known 2$\sigma$ tension in the measurements of the solar $\Delta m^2$ between KamLAND and SNO/Super-KamioKANDE. Precise determination of the solar $\Delta m^2$ is especially important in connection with current and future long baseline CP violation measurements. Reference \cite{Seo:2018rrb} points out that currently running short baseline reactor neutrino experiments, Daya Bay and RENO, can also constrain solar $\Delta m^2$ value as demonstrated by a GLoBES simulation with a limited systematic uncertainty consideration. In this work, the publicly available data, from Daya Bay (1,958 days) and RENO (2,200 days) are used to constrain the solar $\Delta m^2$. Verification of our method through $\Delta m^2_{ee}$ and $\sin^2 \theta_{13}$ measurements is discussed in Appendix A. Using this verified method, reasonable constraints on the solar $\Delta m^2$ are obtained using above Daya Bay and RENO data, both individually and combined. We find that the combined data of Daya Bay and RENO set an upper limit on the solar $\Delta m^2$ of 18 $\times 10^{-5}$ eV$^2$ at the 95% C.L., including both systematic and statistical uncertainties. This constraint is slightly more than twice the KamLAND value. As this combined result is still statistics limited, even though driven by Daya Bay data, the constraint will improve with the additional running of this experiment.Comment: 8 pages, 6 figures, 2 tables. This paper is a follow up of a Monte Carlo study reported in arXiv:1808.09150 by two of the authors. The current paper uses actual data from Daya Bay and RENO that was not previously available and this is the 1st "combined" result using this new experimental data. A new figure is added. Some modifications of the tex

Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial

Introduction:Decreased plasma vitamin D (VD) levels are linked to cardiovascular damage. However, clinical trials have not demonstrated a benefit of VD supplements on left ventricular (LV) remodelling. Anterior ST-elevation acute myocardial infarction (STEMI) is the best human model to study the effect of treatments on LV remodelling. We present a proof-of-concept study that aims to investigate whether VD improves LV remodelling in patients with anterior STEMI. Methods and analysis:The VITamin D in Acute Myocardial Infarction (VITDAMI) trial is a multicentre, randomised, double-blind, placebo-controlled trial. 144 patients with anterior STEMI will be assigned to receive calcifediol 0.266 mg capsules (Hidroferol SGC)/15 days or placebo on a 2:1 basis during 12 months. Primary objective:to evaluate the effect of calcifediol on LV remodelling defined as an increase in LV end-diastolic volume >= 10\% (MRI). Secondary objectives:change in LV end-diastolic and end-systolic volumes, ejection fraction, LV mass, diastolic function, sphericity index and size of fibrotic area; endothelial function; plasma levels of aminoterminal fragment of B-type natriuretic peptide, galectin-3 and monocyte chemoattractant protein-1; levels of calcidiol (VD metabolite) and other components of mineral metabolism (fibroblast growth factor-23 (FGF-23), the soluble form of its receptor klotho, parathormone and phosphate). Differences in the effect of VD will be investigated according to the plasma levels of FGF-23 and klotho. Treatment safety and tolerability will be assessed. This is the first study to evaluate the effect of VD on cardiac remodelling in patients with STEMI. Ethics and dissemination: This trial has been approved by the corresponding Institutional Review Board (IRB) and National Competent Authority (Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS)). It will be conducted in accordance with good clinical practice (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use-Good Clinical Practice (ICH-GCP)) requirements, ethical principles of the Declaration of Helsinki and national laws. The results will be submitted to indexed medical journals and national and international meetings.The VITDAMI trial is an investigator initiated study, sponsored by the Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD). Funding has been obtained from Fondo de Investigaciones Sanitarias (PI14/01567; http://www.isciii.es/) and Spanish Society of Cardiology (http://secardiologia.es/). In addition, the study medication has been provided freely by the pharmaceutical Company FAES FARMA S.A. (Leioa, Vizcaya, Spain; http://faesfarma.com/). This company was the only funder who collaborated in study design (IG-H).S

The reactor neutrino anomaly: status and recent developments

The observed antineutrino flux from nuclear reactors is consistently lower thanpredicted. This anomaly could hint at oscillations of active neutrinos into anew sterile neutrino species, or it could simply be a reflection ofunderestimated systematic uncertainties in the theoretical flux prediction. Wereview the status of both hypotheses in view of recent developments. Inparticular, we scrutinize recent Daya Bay results, which aim to determinewhether the deficit depends on the isotope from which neutrinos are produced (aswould be likely if the problem is with the flux prediction), or is independentthereof (as would be expected if the sterile neutrino hypothesis is true). Wealso comment on new short-baseline data, and we discuss reactor data in thecontext of a global fit